Header Logo

Connection

PETER HOTEZ to Vaccines

Back to Details
This is a "connection" page, showing publications PETER HOTEZ has written about Vaccines.
PETER HOTEZ
Connection Strength
20.673
Vaccines
  1. The zebrafish as a potential model for vaccine and adjuvant development. Expert Rev Vaccines. 2024 Jan-Dec; 23(1):535-545.
    View in: PubMed
    Score: 0.646
  2. Vaccine value profile for Hookworm. Vaccine. 2024 Jul 25; 42(19S1):S25-S41.
    View in: PubMed
    Score: 0.621
  3. Neglected tropical disease vaccines: hookworm, leishmaniasis, and schistosomiasis. Vaccine. 2023 Nov 03; 41 Suppl 2:S176-S179.
    View in: PubMed
    Score: 0.620
  4. Vaccine Preventable Disease and Vaccine Hesitancy. Med Clin North Am. 2023 Nov; 107(6):979-987.
    View in: PubMed
    Score: 0.610
  5. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease. Front Cell Infect Microbiol. 2023; 13:1106315.
    View in: PubMed
    Score: 0.592
  6. COVID-19 vaccines: the imperfect instruments of vaccine diplomacy. J Travel Med. 2022 12 27; 29(8).
    View in: PubMed
    Score: 0.588
  7. Malnutrition vaccines for an imminent global food catastrophe. Trends Pharmacol Sci. 2022 12; 43(12):994-997.
    View in: PubMed
    Score: 0.576
  8. Preclinical advances and the immunophysiology of a new therapeutic Chagas disease vaccine. Expert Rev Vaccines. 2022 09; 21(9):1185-1203.
    View in: PubMed
    Score: 0.568
  9. Communicating science and protecting scientists in a time of political instability. Trends Mol Med. 2022 03; 28(3):173-175.
    View in: PubMed
    Score: 0.551
  10. The yin and yang of human soil-transmitted helminth infections. Int J Parasitol. 2021 12; 51(13-14):1243-1253.
    View in: PubMed
    Score: 0.543
  11. Immunizations and vaccines: a decade of successes and reversals, and a call for 'vaccine diplomacy'. Int Health. 2019 09 02; 11(5):331-333.
    View in: PubMed
    Score: 0.467
  12. "Running the Gauntlet": Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a "Call to Action". Hum Vaccin Immunother. 2019; 15(10):2235-2242.
    View in: PubMed
    Score: 0.462
  13. America and Europe's new normal: the return of vaccine-preventable diseases. Pediatr Res. 2019 06; 85(7):912-914.
    View in: PubMed
    Score: 0.451
  14. Advancing the Development of a Human Schistosomiasis Vaccine. Trends Parasitol. 2019 02; 35(2):104-108.
    View in: PubMed
    Score: 0.442
  15. Minutes to midnight: Turning back the Doomsday Clock through neglected disease vaccine diplomacy. PLoS Negl Trop Dis. 2018 09; 12(9):e0006676.
    View in: PubMed
    Score: 0.437
  16. Vaccines Hesitancy and the Dermatologist. Skinmed. 2018; 16(4):219-221.
    View in: PubMed
    Score: 0.430
  17. The global fight to develop antipoverty vaccines in the anti-vaccine era. Hum Vaccin Immunother. 2018; 14(9):2128-2131.
    View in: PubMed
    Score: 0.425
  18. Russian-United States vaccine science diplomacy: Preserving the legacy. PLoS Negl Trop Dis. 2017 May; 11(5):e0005320.
    View in: PubMed
    Score: 0.399
  19. Developing and financing neglected disease vaccines in our new era of "blue marble health" and the anthropocene epoch. Vaccine. 2017 09 25; 35(40):5403-5405.
    View in: PubMed
    Score: 0.393
  20. Human anthelminthic vaccines: Rationale and challenges. Vaccine. 2016 06 24; 34(30):3549-55.
    View in: PubMed
    Score: 0.371
  21. Advancing a vaccine to prevent hookworm disease and anemia. Vaccine. 2016 06 03; 34(26):3001-3005.
    View in: PubMed
    Score: 0.368
  22. New Vaccines for the World's Poorest People. Annu Rev Med. 2016; 67:405-17.
    View in: PubMed
    Score: 0.354
  23. Combating the next lethal epidemic. Science. 2015 Apr 17; 348(6232):296-7.
    View in: PubMed
    Score: 0.345
  24. "Vaccine diplomacy": historical perspectives and future directions. PLoS Negl Trop Dis. 2014 Jun; 8(6):e2808.
    View in: PubMed
    Score: 0.326
  25. The Human Hookworm Vaccine. Vaccine. 2013 Apr 18; 31 Suppl 2:B227-32.
    View in: PubMed
    Score: 0.300
  26. Vaccinomics for the major blood feeding helminths of humans. OMICS. 2011 Sep; 15(9):567-77.
    View in: PubMed
    Score: 0.264
  27. A handful of 'antipoverty' vaccines exist for neglected diseases, but the world's poorest billion people need more. Health Aff (Millwood). 2011 Jun; 30(6):1080-7.
    View in: PubMed
    Score: 0.263
  28. New antipoverty drugs, vaccines, and diagnostics: a research agenda for the US President's Global Health Initiative (GHI). PLoS Negl Trop Dis. 2011; 5(5):e1133.
    View in: PubMed
    Score: 0.263
  29. Vaccines to combat the neglected tropical diseases. Immunol Rev. 2011 Jan; 239(1):237-70.
    View in: PubMed
    Score: 0.256
  30. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol. 2010 Nov; 8(11):814-26.
    View in: PubMed
    Score: 0.253
  31. Peace through vaccine diplomacy. Science. 2010 Mar 12; 327(5971):1301.
    View in: PubMed
    Score: 0.242
  32. Neglected tropical disease vaccines. Biologicals. 2009 Jun; 37(3):160-4.
    View in: PubMed
    Score: 0.226
  33. Multivalent anthelminthic vaccine to prevent hookworm and schistosomiasis. Expert Rev Vaccines. 2008 Aug; 7(6):745-52.
    View in: PubMed
    Score: 0.216
  34. Hookworm vaccines. Clin Infect Dis. 2008 Jan 15; 46(2):282-8.
    View in: PubMed
    Score: 0.208
  35. Use of the air pouch model to investigate immune responses to a hookworm vaccine containing the Na-ASP-2 protein in rats. Parasite Immunol. 2008 Jan; 30(1):53-6.
    View in: PubMed
    Score: 0.208
  36. Hookworm vaccines: past, present, and future. Lancet Infect Dis. 2006 Nov; 6(11):733-41.
    View in: PubMed
    Score: 0.192
  37. The antipoverty vaccines. Vaccine. 2006 Jul 26; 24(31-32):5787-99.
    View in: PubMed
    Score: 0.186
  38. An ounce of prevention on a budget: a nonprofit approach to developing vaccines against neglected diseases. Expert Rev Vaccines. 2006 Apr; 5(2):189-98.
    View in: PubMed
    Score: 0.184
  39. Biochemical characterization and vaccine potential of a heme-binding glutathione transferase from the adult hookworm Ancylostoma caninum. Infect Immun. 2005 Oct; 73(10):6903-11.
    View in: PubMed
    Score: 0.178
  40. The impact of vaccine-linked chemotherapy on liver health in a mouse model of chronic Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2023 Nov; 17(11):e0011519.
    View in: PubMed
    Score: 0.156
  41. Factors, enablers and challenges for COVID-19 vaccine development. BMJ Glob Health. 2023 06; 8(6).
    View in: PubMed
    Score: 0.151
  42. Vaccine access, equity and justice: COVID-19 vaccines and vaccination. BMJ Glob Health. 2023 06; 8(6).
    View in: PubMed
    Score: 0.151
  43. Progress in vaccine development for infectious diseases-a Keystone Symposia report. Ann N Y Acad Sci. 2023 06; 1524(1):65-86.
    View in: PubMed
    Score: 0.150
  44. Vaxi-DL: An Artificial Intelligence-Enabled Platform for Vaccine Development. Methods Mol Biol. 2023; 2673:305-316.
    View in: PubMed
    Score: 0.147
  45. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-na?ve adults. Vaccine. 2022 10 06; 40(42):6084-6092.
    View in: PubMed
    Score: 0.144
  46. Creation of a Global Vaccine Risk Index. PLoS One. 2022; 17(8):e0272784.
    View in: PubMed
    Score: 0.143
  47. Effectiveness of vaccination mandates in improving uptake of COVID-19 vaccines in the USA. Lancet. 2022 08 13; 400(10351):535-538.
    View in: PubMed
    Score: 0.142
  48. Advancing a Human Onchocerciasis Vaccine From Antigen Discovery to Efficacy Studies Against Natural Infection of Cattle With Onchocerca ochengi. Front Cell Infect Microbiol. 2022; 12:869039.
    View in: PubMed
    Score: 0.140
  49. Vaxi-DL: A web-based deep learning server to identify potential vaccine candidates. Comput Biol Med. 2022 06; 145:105401.
    View in: PubMed
    Score: 0.139
  50. Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon. PLoS Negl Trop Dis. 2021 10; 15(10):e0009732.
    View in: PubMed
    Score: 0.135
  51. Vaccines as instruments of foreign policy. The new vaccines for tropical infectious diseases may have unanticipated uses beyond fighting diseases. EMBO Rep. 2001 Oct; 2(10):862-8.
    View in: PubMed
    Score: 0.135
  52. Identification of vaccine targets in pathogens and design of a vaccine using computational approaches. Sci Rep. 2021 09 02; 11(1):17626.
    View in: PubMed
    Score: 0.134
  53. COVID-19 and the rise of anti-science. Expert Rev Vaccines. 2021 03; 20(3):227-229.
    View in: PubMed
    Score: 0.129
  54. NTDs in the 2020s: An epic struggle of effective control tools versus the Anthropocene. PLoS Negl Trop Dis. 2020 09; 14(9):e0007872.
    View in: PubMed
    Score: 0.126
  55. Anti-science extremism in America: escalating and globalizing. Microbes Infect. 2020 Nov - Dec; 22(10):505-507.
    View in: PubMed
    Score: 0.126
  56. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial. Lancet Infect Dis. 2021 02; 21(2):275-285.
    View in: PubMed
    Score: 0.125
  57. The potential economic value of a therapeutic Chagas disease vaccine for pregnant women to prevent congenital transmission. Vaccine. 2020 04 03; 38(16):3261-3270.
    View in: PubMed
    Score: 0.121
  58. The 2016 California policy to eliminate nonmedical vaccine exemptions and changes in vaccine coverage: An empirical policy analysis. PLoS Med. 2019 12; 16(12):e1002994.
    View in: PubMed
    Score: 0.119
  59. The rise or fall of neglected tropical diseases in East Asia Pacific. Acta Trop. 2020 Feb; 202:105182.
    View in: PubMed
    Score: 0.117
  60. Antibody responses against the vaccine antigens Ov-103 and Ov-RAL-2 are associated with protective immunity to Onchocerca volvulus infection in both mice and humans. PLoS Negl Trop Dis. 2019 09; 13(9):e0007730.
    View in: PubMed
    Score: 0.117
  61. A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area. Vaccine. 2019 10 08; 37(43):6500-6509.
    View in: PubMed
    Score: 0.117
  62. The Salzburg Statement on Vaccination Acceptance. J Health Commun. 2019; 24(5):581-583.
    View in: PubMed
    Score: 0.115
  63. Economic value of a therapeutic Chagas vaccine for indeterminate and Chagasic cardiomyopathy patients. Vaccine. 2019 06 19; 37(28):3704-3714.
    View in: PubMed
    Score: 0.114
  64. Science in the fight to uphold the rights of children. PLoS Biol. 2018 09; 16(9):e3000010.
    View in: PubMed
    Score: 0.109
  65. Cutaneous and subcutaneous granulomata formation in mice immunized and challenged with third-stage infective hookworm (Ancylostoma caninum) larvae. Acta Trop. 1998 Jun; 69(3):229-38.
    View in: PubMed
    Score: 0.107
  66. The poverty-related neglected diseases: Why basic research matters. PLoS Biol. 2017 Nov; 15(11):e2004186.
    View in: PubMed
    Score: 0.103
  67. Vaccines for hookworm infection. Pediatr Infect Dis J. 1997 Oct; 16(10):935-40.
    View in: PubMed
    Score: 0.102
  68. Onchocerca volvulus: The Road from Basic Biology to a Vaccine. Trends Parasitol. 2018 01; 34(1):64-79.
    View in: PubMed
    Score: 0.102
  69. Genetic Adjuvantation of a Cell-Based Therapeutic Vaccine for Amelioration of Chagasic Cardiomyopathy. Infect Immun. 2017 09; 85(9).
    View in: PubMed
    Score: 0.101
  70. Yeast-expressed recombinant As16 protects mice against Ascaris suum infection through induction of a Th2-skewed immune response. PLoS Negl Trop Dis. 2017 Jul; 11(7):e0005769.
    View in: PubMed
    Score: 0.101
  71. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine. PLoS Negl Trop Dis. 2017 02; 11(2):e0005385.
    View in: PubMed
    Score: 0.098
  72. A simple fluorescence-based assay for quantification of the Toll-Like Receptor agonist E6020 in vaccine formulations. Vaccine. 2017 03 07; 35(10):1410-1416.
    View in: PubMed
    Score: 0.098
  73. The Immunomodulatory Role of Adjuvants in Vaccines Formulated with the Recombinant Antigens Ov-103 and Ov-RAL-2 against Onchocerca volvulus in Mice. PLoS Negl Trop Dis. 2016 07; 10(7):e0004797.
    View in: PubMed
    Score: 0.094
  74. Advancing a vaccine to prevent human schistosomiasis. Vaccine. 2016 06 03; 34(26):2988-2991.
    View in: PubMed
    Score: 0.092
  75. Modeling the economic and epidemiologic impact of hookworm vaccine and mass drug administration (MDA) in Brazil, a high transmission setting. Vaccine. 2016 Apr 27; 34(19):2197-206.
    View in: PubMed
    Score: 0.092
  76. Vaccines to combat river blindness: expression, selection and formulation of vaccines against infection with Onchocerca volvulus in a mouse model. Int J Parasitol. 2014 Aug; 44(9):637-46.
    View in: PubMed
    Score: 0.081
  77. Global progress towards eliminating gastrointestinal helminth infections. Curr Opin Gastroenterol. 2014 Jan; 30(1):18-24.
    View in: PubMed
    Score: 0.079
  78. Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasis. Hum Vaccin Immunother. 2013 Nov; 9(11):2342-50.
    View in: PubMed
    Score: 0.077
  79. Biophysical and formulation studies of the Schistosoma mansoni TSP-2 extracellular domain recombinant protein, a lead vaccine candidate antigen for intestinal schistosomiasis. Hum Vaccin Immunother. 2013 Nov; 9(11):2351-61.
    View in: PubMed
    Score: 0.076
  80. New vaccines for neglected parasitic diseases and dengue. Transl Res. 2013 Sep; 162(3):144-55.
    View in: PubMed
    Score: 0.075
  81. Innovation for the 'bottom 100 million': eliminating neglected tropical diseases in the Americas. Adv Exp Med Biol. 2013; 764:1-12.
    View in: PubMed
    Score: 0.074
  82. Molecular mechanisms of hookworm disease: stealth, virulence, and vaccines. J Allergy Clin Immunol. 2012 Jul; 130(1):13-21.
    View in: PubMed
    Score: 0.071
  83. Selection and quantification of infection endpoints for trials of vaccines against intestinal helminths. Vaccine. 2011 May 09; 29(20):3686-94.
    View in: PubMed
    Score: 0.065
  84. Neutralizing antibodies to the hookworm hemoglobinase Na-APR-1: implications for a multivalent vaccine against hookworm infection and schistosomiasis. J Infect Dis. 2010 May 15; 201(10):1561-9.
    View in: PubMed
    Score: 0.061
  85. Modelling heterogeneity and the impact of chemotherapy and vaccination against human hookworm. J R Soc Interface. 2008 Nov 06; 5(28):1329-41.
    View in: PubMed
    Score: 0.055
  86. Reinventing Guantanamo: from detainee facility to Center for Research on Neglected Diseases of Poverty in the Americas. PLoS Negl Trop Dis. 2008 Feb 27; 2(2):e201.
    View in: PubMed
    Score: 0.053
  87. Protective immunity elicited by ultraviolet-irradiated third-stage infective hookworm (Necator americanus and Ancylostoma caninum) larvae in mice and hamsters. Southeast Asian J Trop Med Public Health. 2006 Sep; 37(5):885-95.
    View in: PubMed
    Score: 0.047
  88. Antibodies against a secreted protein from hookworm larvae reduce the intensity of hookworm infection in humans and vaccinated laboratory animals. FASEB J. 2005 Oct; 19(12):1743-5.
    View in: PubMed
    Score: 0.044
  89. Immunogenicity of the hookworm Na-ASP-2 vaccine candidate: characterization of humoral and cellular responses after vaccination in the Sprague Dawley rat. Hum Vaccin. 2005 May-Jun; 1(3):123-8.
    View in: PubMed
    Score: 0.043
  90. Hookworm: "the great infection of mankind". PLoS Med. 2005 Mar; 2(3):e67.
    View in: PubMed
    Score: 0.043
  91. X-ray structure of Na-ASP-2, a pathogenesis-related-1 protein from the nematode parasite, Necator americanus, and a vaccine antigen for human hookworm infection. J Mol Biol. 2005 Feb 25; 346(3):801-14.
    View in: PubMed
    Score: 0.042
  92. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial. Lancet Infect Dis. 2024 Jul; 24(7):760-774.
    View in: PubMed
    Score: 0.040
  93. Helminth vaccines: from mining genomic information for vaccine targets to systems used for protein expression. Int J Parasitol. 2003 May; 33(5-6):621-40.
    View in: PubMed
    Score: 0.038
  94. Cutaneous and subcutaneous mast cell and eosinophil responses after challenge in mice vaccinated with living infective third-stage hookworm larvae. Chin Med J (Engl). 1999 Nov; 112(11):1020-3.
    View in: PubMed
    Score: 0.030
  95. What Is the Value of Different Zika Vaccination Strategies to Prevent and Mitigate Zika Outbreaks? J Infect Dis. 2019 08 09; 220(6):920-931.
    View in: PubMed
    Score: 0.029
  96. Histochemical alterations of infective third-stage hookworm larvae (L3) in vaccinated mice. Southeast Asian J Trop Med Public Health. 1999 Jun; 30(2):356-64.
    View in: PubMed
    Score: 0.029
  97. Resurgence of Vaccine-Preventable Diseases in Venezuela as a Regional Public Health Threat in the Americas. Emerg Infect Dis. 2019 04; 25(4):625-632.
    View in: PubMed
    Score: 0.028
  98. IgG Induced by Vaccination With Ascaris suum Extracts Is Protective Against Infection. Front Immunol. 2018; 9:2535.
    View in: PubMed
    Score: 0.028
  99. Protective immunity in mice elicited by living infective third-stage hookworm larvae (Shanghai strain of Ancylostoma caninum). Chin Med J (Engl). 1998 Jan; 111(1):43-8.
    View in: PubMed
    Score: 0.026
  100. An enzymatically inactivated hemoglobinase from Necator americanus induces neutralizing antibodies against multiple hookworm species and protects dogs against heterologous hookworm infection. FASEB J. 2009 Sep; 23(9):3007-19.
    View in: PubMed
    Score: 0.014
  101. Variation between ASP-1 molecules from Ancylostoma caninum in China and the United States. J Parasitol. 2000 Feb; 86(1):181-5.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.